

Note: Page numbers followed by the letters *f* and *t* indicate figures and tables, respectively.

A

- Abdomen, neonatal assessment of, L10
- Abdominopelvic pain, lower, W1–W6
- Abortion, spontaneous, D1–D5
- Abruptio placenta, F2–F4
 - clinical characteristics of, F3
 - incidence of, F2–F3
 - management of, F3–F4
 - transport with, N3
- Abscess, breastfeeding and, M12–M13
- Absolute Band Count, J10*f*
- Absolute Neutrophil Count (ANC), J10*f*
- Absolute risk, definition of, V13
- Abuse
 - domestic, Y1–Y3
 - sexual, J69–J70, X1, X4–X5
- ACE inhibitors, for chronic hypertension in pregnancy, E6
- Acquired immune deficiency syndrome (AIDS), J38. *See also* HIV infection
- Activity, postpartum, recommendations for, I8
- Acyclovir
 - for congenital herpes simplex virus, J16, J17
 - for genital herpes, J50–J53
 - in pregnancy, J53
- Adolescents. *See also* Children, prepubescent breast masses in, P10
- AFI. *See* Amniotic fluid index
- AFP. *See* Alpha fetoprotein test
- AGC. *See* Atypical glandular cells
- Age
 - gestational assessment of neonatal, L11–L16
 - prenatal, B1–B2, E11
 - parental, and spontaneous abortion, D2
- AIDS, J38. *See also* HIV infection
- Alcohol use, maternal
 - and birth outcomes, A4, C4
 - and fetal growth restriction, E10
 - rate of, A5, A5*f*
 - and spontaneous abortion, D1
- Alpha fetoprotein test (AFP), for congenital anomalies, C7
- Alzheimer disease, estrogen and, V4
- Ambulation, for protraction/arrest disorders, G5
- Amenorrhea, U1–U4
 - definition of, U1
 - etiology of, U2–U4
 - evaluation of, U1, U5*f*
 - iatrogenic, U4
 - treatment of, U1–U4
- Amikacin, for newborns, J12*t*
- Amniocentesis, for congenital anomalies, C7
- Amniotic fluid index (AFI), H16
- Amniotomy, for protraction/arrest disorders, G5
- Ampicillin, for newborns, J12*t*
- Anal warts, treatment of, J57
- ANC. *See* Absolute Neutrophil Count
- Anembryonic pregnancy, D2
- Anemia, prenatal care for, B3
- Anorexia nervosa, and amenorrhea, U3
- Anoxia, asphyxia and, K1
- Anoxic hypoxia, K1
- Antibiotics
 - and congenital defects, C4
 - for endometritis, I6
 - for GBS infections, J24
 - for perinatal infections, J11, J12*t*–J13*t*
 - for PROM, F6
- Antibodies, in neonates, J2, J3*t*
- Antibody screen, prenatal, B4
- Anticoagulants, and congenital defects, C4
- Anticonvulsants, and congenital defects, C4
- Antidepressants, and congenital defects, C4
- Antihypertensives
 - for chronic hypertension in pregnancy, E6
 - and congenital defects, C4
 - for preeclampsia, E5–E6
- Anus, neonatal assessment of, L10
- Apgar scoring system, F15, K6, K6*t*
- Apnea, primary vs. secondary, in asphyxia, K6–K7
- Arrest disorders, G4–G5, G4*t*
- ASCUS. *See* Atypical squamous cells of undetermined significance
- ASH. *See* Asymmetrical septal hypertrophy
- Asherman syndrome, U2
- Asphyxia, perinatal, K1–K11
 - anticipation of, K1, L5
 - causes of, K1, K2*t*–K3*t*
 - definitions of, K1
 - diagnosis of, K4–K8, L5–L6
 - effects of, K5*t*
 - in infants of diabetic mothers, E37
 - vs. neonatal, K1
 - outcome of, K10–K11
 - pathophysiologic mechanisms of, K1–K4, K5*t*
 - postasphyxia complications, K8–K10
 - prevention of, K1
 - severity of, K6–K8
 - significance of, K1
- Aspiration, fine-needle, in breast disease diagnosis, P6

Assessment, neonatal. *See* Neonatal assessment
 Asymmetrical septal hypertrophy (ASH), in infants of diabetic mothers, E36
 Asymptomatic bacteriuria, B4
 Atresia, esophageal, L30–L31
 Atrophic vulvovaginitis, R4*t*
 Atypical glandular cells (AGC), management of, Q5, Q12*f*
 Atypical squamous cells of undetermined significance (ASCUS), management of, Q5, Q9*f*, Q10*f*
 Autosomal dominant gene defects, C1
 Autosomal recessive gene defects, C1

B

Baby blues, instructions for mothers on, I10
 Bacteriuria, asymptomatic, B4–B5
 Bag and mask ventilation, in neonatal resuscitation, F20, F21–F22, F26*t*
 Ballard examination, L11–L12
 Barrier methods of contraception, S10–S11
 Basal body temperature (BBT) chart
 in infertility evaluation, T5, T12
 sample, T13*f*
 technique for, T12–T13
 Bilirubin production
 changes in, L40–L41
 monitoring of, L41–L42
 Biophysical profile, for fetal monitoring, H16, H17*t*
 Birth control. *See* Contraception; Family planning
 Birth defects. *See* Congenital anomalies
 Birth injury, in infants of diabetic mothers, E37
 Birth weight, low
 and mortality, A3, A3*f*
 rate of, A3*f*
 Bleeding
 abnormal uterine, V19
 dysfunctional uterine, U5–U8
 pediatric vaginal, X4–X7
 postpartum vaginal, I8
 Blighted ovum, D2
 Blood flow
 umbilical, H2
 uterine, H1–H2
 Blood gas analysis, post-asphyxic, K7
 Blood tests
 for congenital anomalies, C7
 in prenatal care, B3–B4
 Blood type, in prenatal care, B4
 Body mass index nomogram, E32
 Bone fractures, hormone therapy and, V11, V15*f*
 Botryoides, sarcoma, X5
 Bottlefeeding, instructions for, I9

Bradycardia, fetal, H6–H7, H7*f*
 Breast(s)
 abscess, M12–M13
 benign conditions of, P9–P10, P11*t*
 breastfeeding-associated problems with, M11–M12
 engorgement of, M11–M12
 pain in, P9
 plugged ducts in, M12
 Breast cancer
 breastfeeding with, M3
 hormone therapy and, V10, V14*f*
 incidence of, P1
 pregnancy and, P10
 risk factors for, P1
 Breast disease, P1–P12
 diagnosis of, P2–P6
 algorithm for, P7*f*
 clinical exam in, P3–P4
 fine-needle aspiration in, P6
 mammography in, P4–P6
 self-exam in, P2–P3
 management of, P6, P12
 signs of, P8–P9
 Breast implants, silicone, P10
 Breast masses
 in adolescents, P10
 management of, P6
 during pregnancy, P10
 signs of, P8
 Breast milk
 allergic reaction to, M7
 collection of, M14–M15
 storage of, M15
 strong ejection reflex, M11
 Breast milk jaundice, L45
 Breast self-examination (BSE), P2–P3
 Breastfeeding, M1–M16
 advantages of, M1–M2
 barriers to, M16
 cancer and, M3, P10
 complications with, M12–M13
 contraindications for, M3
 disadvantages of, M2
 duration of, M6–M7
 family planning and, M13–M14
 frequency of, M6–M7
 frequently asked questions on, M6–M8
 initiation of, M3–M4
 instructions for, I11
 and jaundice, L45
 management of problems with, M8–M10
 medications during, M3, M13
 positions for, M4, M5*f*
 program goals for, A6, M1
 promotion of, M1

rates of, A6, M1
 BSE. *See* Breast self-examination

C
 Calcium, significance of, L56–L57
 Calcium channel blockers, for chronic hypertension in pregnancy, E6
 Cancer. *See also specific types*
 risk factors for, by ethnicity, P1
Candida albicans, R5f
 and leukorrhea, R3t
 Carbon monoxide, effects of, L38
 Cardiac emergencies, neonatal, assessment of, L25–L27
 Cardiac massage. *See* Chest compressions
 Cardiomyopathy, hypertrophic, in infants of diabetic mothers, E36, E40–E41
 Cardiopulmonary complications
 and cyanosis, L20–L22
 in post-asphyxic neonates, K9
 Cardiovascular complications
 neonatal assessment of, L19–L23
 from perinatal infections, J8
 in post-asphyxic neonates, K8
 Cardiovascular disease (CVD), V5–V6
 hormone therapy and, V9–V10, V16f
 incidence of, V5
 prevention of, V5–V6
 risk factors for, V5
 Carpenter and Coustan criteria, E19, E33
 Catheterization, umbilical vessel, in neonatal resuscitation, F21, F24, F26t
 CBE. *See* Clinical breast examination
 CDH. *See* Congenital diaphragmatic hernia
 Cefotaxime, for newborns, J12f
 Central cyanosis, L19, L20
 Central nervous system (CNS) complications
 from perinatal infections, J8
 in post-asphyxic neonates, K9, K10
 Cephalosporin, for gonorrhea, J58–J59
 Cervical cancer, Q1–Q2
 incidence of, Q1
 mortality rates from, Q1, Q1f
 pap tests and, Q3
 risk factors for, Q3
 Cervical cytology, prenatal, B5
 Cervical intraepithelial neoplasia (CIN), risk factors for, Q2
 Cervical neoplasia, Q2
 Cervical warts, treatment of, J56
 Cervicitis, mucopurulent, J63–J64
 Cervix
 in female infertility, T6
 physiology of, Q2
 Cesarean delivery, vaginal birth after, G6
 Chancroid, J42–J43
 follow-up for, J43
 treatment of, J43
 CHD. *See* Congenital heart disease
 Chemoprophylaxis, selective intrapartum, for GBS disease, J23–J24, J26
 Chest, anomalies of, L18
 Chest compressions, in neonatal resuscitation, F21, F23–F24
 CHF. *See* Congestive heart failure
 Chickenpox. *See* Varicella
 Children, prepubescent, X1–X7
 anatomy of, X1–X2
 breast masses in, P10
 examination of
 equipment for, X3
 positioning for, X3
 specimen collection in, X3
 vaginal inspection in, X3
 STDs in, J70
 vaginal bleeding in, X4–X7
 vaginal microflora of, X2
 vulvovaginitis in, X4
 etiology of, X4
 treatment of, X4
 Chin, neonatal assessment of, L9
 anomalies in, L17
 Chlamydial infections, J62–J63
 follow-up for, J63
 with gonorrhea, J57
 prenatal screening for, B4
 and sex partners, J63
 treatment of, J62–J63
 in pregnancy, J63
 Chorioamnionitis, J7–J8
 Chorionic villus sampling (CVS), for congenital anomalies, C6–C7
 Chromosomal anomalies
 and congenital defects, C2, C8
 and spontaneous abortion, D1
 Chromosomal syndromes, anomalies associated with, L17–L18
 Chronic disease, maternal, and spontaneous abortion, D1
 CIN. *See* Cervical intraepithelial neoplasia
 Climacteric. *See also* Menopause
 definition of, V1
 endocrinology of, V1–V2
 evaluation during, V6, V7t
 Clinical breast examination (CBE)
 frequency of, P12
 technique for, P3–P4
 CMV. *See* Cytomegalovirus
 CNS. *See* Central nervous system
 Cocaine use, and birth outcomes, C3
 Cognitive function, hormone therapy and, V11
 Colon cancer, hormone therapy and, V11

- Colon syndrome, small left, in infants of diabetic mothers, E37
 - Color, neonatal assessment of, L6
 - Colposcopy
 - definition of, Q17
 - guidelines for, Q6
 - Complete abortion, D3, D4*t*
 - Condoms, S11
 - Condyloma acuminata, and leukorrhea, R4*t*
 - Confidence intervals, definition of, V13
 - Congenital anomalies, C1–C8, L28–L39
 - assessment of, L17–L18
 - definitions of, L28–L29
 - etiology of, C1–C5, L28
 - in infants of diabetic mothers, E37, E38*t*
 - multiple, L29
 - prenatal diagnosis of, C6–C7
 - prevention of, B1, C8
 - rate of, A3*f*
 - risk assessment for
 - preconception, B1, C6, C8
 - prenatal, C6, C6*f*, C8
 - significance of, L28
 - as surgical emergencies, L30–L33
 - Congenital complete heart block
 - assessment of, L27
 - occurrence of, L27
 - Congenital diaphragmatic hernia (CDH), L32–L33
 - Congenital heart disease (CHD)
 - clinical signs of, L21–L22
 - cyanosis and, L19–L22
 - hormone therapy and, V15*f*
 - in infants of diabetic mothers, E37
 - x-ray findings with, L22
 - Congenital infections, J13–J20
 - Congenital syndromes, anomalies associated with, L17–L18
 - Congestive heart failure (CHF), neonatal
 - clinical signs of, L22–L23
 - risk factors for, L22
 - Constipation, postpartum, I9
 - Contraception
 - barrier methods, S10–S11
 - emergency, S6–S7
 - implants, S7–S8
 - IUD, S12–S19
 - long-acting injections, S8–S10
 - newer hormonal methods of, S10
 - oral, S2–S7
 - Contraction stress test (CST), for fetal evaluation, H15–H16
 - Contractions, uterine
 - and fetal heart rate, H3, H3*f*, H15–H16
 - normal rates for, H3
 - Cord, umbilical, anomalies of, L18
 - Cordocentesis, C7
 - Corticosteroids, for premature labor, F9
 - CPAP application test, for cyanosis, L21
 - CST. *See* Contraction stress test
 - CVS. *See* Chorionic villus sampling
 - Cyanide, effects of, L38
 - Cyanosis, L19–L22
 - definitions of, L19
 - etiology of, L21–L22
 - pathophysiology of, L20
 - Cyst(s)
 - hymenal, X7
 - pediatric vaginal, X7
 - Cytomegalovirus (CMV) infection, J13–J14, J29
 - and breastfeeding, M3
 - clinical manifestations of, J13–J14, J29
 - diagnosis of, J14, J21, J29
 - epidemiology of, J13
 - etiology of, J13
 - prevention of, J14, J21, J22*t*
 - as teratogen, C3
 - in TORCH complex, J21
 - treatment of, J14, J21, J22*t*, J29
- D
- Deformations
 - definition of, L28–L29
 - sequence of, L29
 - Delivery
 - estimated date of, calculation of, B1
 - with premature labor, preparation for, F10
 - vaginal birth after cesarean, G6
 - Dementia, hormone therapy and, V11
 - Depo-Provera, S8–S10
 - Depression. *See* Asphyxia
 - Development, fetal, definition of, L28
 - DGI. *See* Disseminated gonococcal infection
 - Diabetes, maternal, E17–E27. *See also* Infants of diabetic mothers
 - classification of, E24, E31
 - and congenital anomalies, C3
 - diagnosis of, E18–E19, E33
 - family planning with, E26
 - future pregnancy considerations with, E26
 - gestational
 - classification of, E19
 - diagnosis of, E18–E19
 - management of, E19–E26
 - pathophysiology of, E17
 - screening for, E17–E18
 - incidence of, E17
 - management of, E19–E26
 - pathophysiology of, E17
 - preconception care for, B1, E26
 - screening for, B5, E17–E18, E31
 - significance of, E17

- Diagnostic excisional procedure, Q17
 - Diagonal conjugate, B3, B3f
 - Diaphragm (anatomical), congenital eventration of, L32–L33
 - Diaphragm (contraceptive), S10–S11
 - Diaphragmatic hernia, congenital (CDH), L32–L33
 - Diet, management of gestational diabetes with, E20–E22
 - Discharge, of neonates, assessment before, L4–L5
 - Disruptions, definition of, L29
 - Disseminated gonococcal infection (DGI), treatment of, J60, J61
 - Diuretics, for chronic hypertension in pregnancy, E6–E7
 - Domestic violence, Y1–Y3
 - cycle of, Y1
 - documentation of, Y2
 - privacy and, Y2–Y3
 - referrals for, Y2
 - resources on, Y2
 - screening for, Y2
 - Dopamine, in neonatal resuscitation, F19, F27t
 - Down syndrome, prenatal screening for, B5–B6, C7
 - Drugs. *See* Medications
 - Dubowitz score, L11
 - Duct ectasia, P11t
 - Dysfunctional uterine bleeding, U5–U8
 - Dystocia, G4–G5
 - etiology of, G4–G5
 - management of, G5
- E**
- EA. *See* Esophageal atresia
 - Ears, neonatal assessment of, L9
 - anomalies in, L17
 - Eclampsia. *See* Preeclampsia-eclampsia
 - Ectasia, duct, P11t
 - Ectoparasitic infections, J67–J68
 - Ectopic pregnancy
 - clinical features of, D6–D7, D7f
 - diagnosis of, D6–D7, D8f
 - incidence of, D5
 - management of, D9–D10
 - pain in, D6, D7f
 - risk factors for, D5
 - ruptured, D6–D7, D7f
 - sites and frequency of, D5, D5f
 - EDD. *See* Estimated date of delivery
 - Education, in prenatal care, B7–B8
 - Embryonic regression, D2
 - Emergency oral contraception, S6–S7
 - Emergency transport
 - maternal, N1–N4
 - neonatal, O1–O3
 - Endocarditis, treatment of, J60
 - Endocervical assessment, Q17
 - Endocervical sampling, Q17
 - Endocrine disease, extragonadal, and amenorrhea, U4
 - Endometrial biopsy, in infertility evaluation, T5
 - Endometritis, I6
 - diagnosis of, I6
 - management of, I6
 - risk factors for, I6
 - Endotracheal intubation, in neonatal resuscitation, F20, F22–F23, F26t
 - Engorgement, breast, M11–M12
 - Environmental factors, and spontaneous abortion, D1
 - Epilepsy, maternal, and congenital defects, C4
 - Epinephrine, in neonatal resuscitation, F18, F21, F27t
 - Epithelial infections, J54–J57
 - Erythrocytosis. *See* Polycythemia
 - Esophageal atresia (EA), L30–L31
 - Estimated date of delivery (EDD), calculation of, B1
 - Estrogen
 - menopausal replacement of, V7, V7t
 - alternatives to, V19–V20, V20t
 - with patch, V18
 - Ethnicity, and cancer, P1
 - Exercise, postpartum guidelines for, I10f, I10–I11, I11f
 - Eyes, neonatal assessment of, L9
 - anomalies in, L17
- F**
- Family planning, S1–S19. *See also* Contraception
 - breastfeeding and, M13–M14
 - definition of, S1
 - with maternal diabetes, E26
 - services provided by IHS, S1–S2
 - surgical sterilization in, S11–S12
 - Family violence, Y1–Y3
 - FAS. *See* Fetal alcohol syndrome
 - Feet, neonatal anomalies in, L18
 - Feminization syndrome, testicular, U3
 - Fertility. *See* Infertility
 - Fetal alcohol syndrome (FAS), L33–L36
 - definition of, L33–L34
 - diagnosis of, L34–L35
 - etiology of, A4
 - follow-up with, L35–L36
 - management of, L35–L36
 - mechanisms of, L34
 - physical characteristics with, L34–L35
 - prevention of, L35–L36

scope of, L33–L34

Fetal bradycardia, H6–H7, H7f

Fetal development, definition of, L28

Fetal growth restriction (FGR), E10–E16

- case study on, E15–E16
- definition of, E10
- diagnosis of, E11–E12
- etiology of, E10–E11
- incidence of, E10
- infants with (See Small-for-gestational-age (SGA) infants)
- management of, E12–E13
- obstetrical signs of, L15
- risk factors for, E10–E11, L15
- significance of, E10
- symmetric vs. asymmetric, E11–E12

Fetal heart rate (FHR) monitoring, H1–H17

- abnormal patterns in, H11–H13, H12t, H14f
- antepartum, tests for, H14–H17
- for asphyxia, K4
- baseline rate in, H3, H3f
- baseline variability in, H3–H6, H4f
 - beat to beat, H3–H4
 - decreased, H4–H5, H5f
 - increased, H5–H6, H6f
 - normal, H4
- bradycardia in, H6–H7, H7f
- definition of, H1
- pattern recognition and interpretation, H3–H11
- periodic changes in, H7–H11
 - accelerations, H7–H8, H8f
 - decelerations, H8–H11, H9f, H10f, H11f, H13
- physiological principles of, H1–H3
- purpose of, H1
- tachycardia in, H7

Fetal heart tones, gestational age and, B2

Fetal monitoring, H1. *See also* Fetal heart rate monitoring

FGR. *See* Fetal growth restriction

Fibroadenoma, P11t

Fifth disease, C2

Fine-needle aspiration, in breast disease

- diagnosis, P6

FISH. *See* Fluorescent in-situ hybridization

Fistula, tracheoesophageal, L30–L31

Fluid balance, in management of preeclampsia, E5

Fluorescent in-situ hybridization (FISH), for congenital anomalies, C7

Foam, spermicidal, S11

Folic acid supplementation, in preconception care, B1

Foot anomalies, L18

Fractures, hormone therapy and, V11, V15f

Friedman, Emmanuel, G1

G

Galactorrhea, P11t, U5f

Galactosemia, and breastfeeding, M3

Ganciclovir, for cytomegalovirus, J14

Gastrointestinal complications

- from perinatal infections, J8
- in post-asphyxic neonates, K8, K10

Gastroschisis, L31–L32

GBS. *See* Group B beta hemolytic streptococcus

Gene defects, single, C1–C2

Genetic counseling

- for congenital anomalies, C6, C6f
- in prenatal care, B5–B6

Genetic heterogeneity, L29

Genetic transmission, of congenital anomalies, C1, C8

Genital herpes simplex virus (HSV) infections, J50–J54

- clinical manifestations of, J51
- with HIV, J51, J53
- management of
 - for first episode, J51
 - obstetric, J51, J53
 - for recurrent episodes, J52
 - for severe disease, J52
- perinatal, J54
- and sex partners, J53

Genital tract abnormalities, and spontaneous abortion, D1

Genital ulcers, infections associated with, J42–J54

Genital warts, J54–J57

- follow-up for, J57
- perinatal, J55
- in pregnancy, J55
- and sex partners, J57
- treatment of, J54–J57

Genitalia

- neonatal assessment of, L10
 - anomalies in, L18
- prepubescent, X1–X2

Gentamicin, for newborns, J12t

German measles. *See* Rubella

Gestational age assessment

- neonatal, L11–L16
 - of LGA infant, L16
 - of postmature infant, L13–L14
 - of premature infant, L12–L13
 - of SGA infant, L15–L16
- prenatal, B1–B2, E11

Gestational diabetes

- classification of, E19
- diagnosis of, E18–E19

- management of, E19–E26
- pathophysiology of, E17
- screening for, E17–E18
- Gestational hypertension, E7
 - definition of, E1, E7
 - prognosis with, E7
- Global index, definition of, V13
- Glucose monitoring, blood, of infants of diabetic mothers, E40
- Goals, program, A1–A6
- Gonads, in amenorrhea, U2–U3
- Gonococcal infections, J57–J67. *See also specific types*
 - in infants/children, J61–J62
 - treatment of, J57
 - disseminated, J60, J61
 - for neonates, J61–J62
 - ophthalmia, J61–J62
 - pharyngeal, J60
 - in pregnancy, J60
- Gonorrhea
 - follow-up for, J59
 - prenatal screening for, B4
 - and sex partners, J59
 - treatment of, J58–J61
 - in pregnancy, J60
- Group B beta hemolytic streptococcus (GBS) infections, J23–J26
 - early-onset form of, J23–J24
 - late-onset form of, J23, J24
 - obstetric management of, J24–J26, J25f
 - prenatal screening for, B4
 - risk factors for, J23, J24
 - treatment of, J23–J24
- Growth aberrations, in infants of diabetic mothers, E37
- Growth restriction, intrauterine (IUGR). *See* Fetal growth restriction
- H
- Hands, neonatal anomalies in, L18
- Hazard ratios, V13
- Head, neonatal assessment of, L8
 - anomalies in, L17
- Health inventories, in prenatal care, B3
- Healthy People 2010 program, objectives of, A1–A6
- Heart, neonatal assessment of, L10
- Heart block, congenital complete, L27
- Heart disease, congenital, L19–L22
- Heart failure, congestive, in neonates, L22–L23
- Heart rate. *See also* Fetal heart rate
 - neonatal assessment of, L6, L7
- Heart tones, fetal, gestational age and, B2
- Heelstick Hct, for infants of diabetic mothers, E40
- Hematologic complications, in post-asphyxiated neonates, K8, K10
- Hemoglobin levels, in prenatal care, B3
- Hemorrhage
 - acute fetal, heart rate with, H12
 - obstetric, F1–F4
 - postpartum, I2–I4
 - causes of, I3
 - definition of, I2
 - management of, I3–I4
 - risk factors for, I3
- Hemorrhagic shock
 - clinical signs of, L19
 - laboratory findings with, L19
 - risk factors for, L19
- Hemorrhoids, postpartum, I9
- Hepatitis, J31–J33
 - and breastfeeding, M3
 - clinical manifestations of, J32
 - diagnosis of, J32, J33
 - forms of, J33t
 - immunologic changes in, J34t
 - management of, J35t
 - postexposure recommendations for, J29t, J36t
 - risk factors for, J32, J35t
 - terminology of, J33t
 - transmission of, J34t
 - treatment of, J32, J33
 - vaccinations for, J29t, J36t
- Hepatitis B surface antigen, prenatal screening for, B4
- Hernia, congenital diaphragmatic, L59–L60
- Heroin use, and birth outcomes, C4
- Herpes simplex virus (HSV) infections
 - and breastfeeding, M3
 - congenital, J15–J17
 - clinical presentation of, J15–J16
 - diagnosis of, J16
 - epidemiology of, J15
 - outcome with, J16
 - pathophysiology of, J15
 - prevention of, J17
 - treatment of, J16
 - diagnosis of, J21
 - genital, J50–J54
 - and leukorrhea, R4t
 - perinatal transmission of, J17
 - prevention of, J21, J22t
 - in TORCH complex, J21
 - treatment of, J21, J22t
- High-grade squamous intraepithelial lesions (HSIL), management of, Q5, Q16f
- Hips, neonatal assessment of, L11
- HIV infection, J38–J42
 - and AIDS, J38

- and breastfeeding, M3
- care planning for, J39–J40
- chancroid and, J42, J43
- counseling for patients with, J39
- diagnostic testing for, J38–J39
 - prenatal, B4
- early intervention for, J38
- with genital herpes, J51, J53
- in infants/children, J42
- initial evaluation with, J39–J40
- partner notification with, J41
- in pregnancy, J41–J42
- Hormonal agents, and congenital defects, C4
- Hormone therapy (HT), V7–V21
 - considerations with, V18–V19
 - contraindications to, V19
 - dosing regimens for, V7t, V13, V18
 - patient decision on, V20–V21
 - recommendations for use of, V11–V13
 - risks with, V9–V11
 - side effects of, V9–V11
 - Women's Health Initiative study of, V8–V16
- Hot flashes
 - definition of, V3
 - in menopause, V3, V18
- HPV. *See* Human papillomavirus
- HSIL. *See* High-grade squamous intraepithelial lesions
- HSV. *See* Herpes simplex virus
- HT. *See* Hormone therapy
- HTLV. *See* Human T-lymphotrophic Virus
- Human immunodeficiency virus. *See* HIV
- Human papillomavirus (HPV), J54–J57
 - and cervical cancer, Q1–Q2
 - follow-up with, J57
 - perinatal, J55
 - in pregnancy, J55
 - and sex partners, J57
 - treatment of, J54–J57
- Human T-lymphotrophic Virus (HTLV), and breastfeeding, M3
- Hyaline membrane disease, L47–L49
 - clinical signs of, L47–L48
 - complications with, L48, L49
 - course of, L48
 - vs. GBS, J23
 - in infants of diabetic mothers, E37
 - risk factors for, L47
 - treatment of, L48–L49
- Hydatidiform mole, D10–D11
 - clinical features of, D11
 - diagnosis of, D11
 - etiology of, D10
 - incidence of, D10
 - management of, D11
- Hydralazine
 - for chronic hypertension in pregnancy, E6
 - for preeclampsia, E5–E6
- Hymenal anatomy, prepubescent, X1
 - child abuse and, X1
- Hymenal cysts, X7
- Hyperbilirubinemia, L41–L44
 - in infants of diabetic mothers, E36
- Hypercarbia, asphyxia and, K1
- Hyperoxia test, for cyanosis, L21
- Hypertension
 - oral contraception with, S4
 - in pregnancy, E1–E9
 - case studies on, E8–E9
 - chronic or latent, E6–E7
 - baseline studies with, E7
 - definition of, E1
 - management of, E6–E7
 - significance of, E6
 - classification of, E1–E2
 - gestational, E1, E7
 - preeclampsia-eclampsia, E2–E6
- Hypertrophy, asymmetrical septal, in infants of diabetic mothers, E36
- Hyperviscosity syndrome, L58–L60
 - definition of, L58
 - in infants of diabetic mothers, E36
- Hypocalcemia, neonatal, L56–L58
 - clinical signs of, L57
 - definitions of, L57
 - in infants of diabetic mothers, E36
 - pathophysiology of, L57
 - risk factors for, L57
 - treatment of, L68
- Hypoglycemia, neonatal, L55–L56
 - clinical signs of, L55
 - definitions of, L55
 - in infants of diabetic mothers, E36
 - pathophysiology of, L55
 - risk factors for, L55
 - screening for, L55–L56
 - treatment of, L56
- Hypomagnesemia, neonatal, in infants of diabetic mothers, E36
- Hypothalamus, in amenorrhea, U3–U4
- Hypoxemia, and fetal bradycardia, H6
- Hypoxia
 - anoxic, K1
 - asphyxia and, K1
 - ischemic, K1
- Hysterosalpingography, in fertility evaluation, T6, T7
- Hysteroscopy, in fertility evaluation, T7

I

- IDM. *See* Infants of diabetic mothers
- Immune globulins

- IgM antibody, in neonates, J2
 - varicella zoster, C2
 - Immune system deficiencies, and perinatal infections, J2
 - Immunization. *See* Vaccinations
 - Implants, contraceptive, S7–S8
 - advantages of, S7
 - contraindications for, S7
 - disadvantages of, S7
 - effectiveness of, S8
 - indications for, S7
 - side effects of, S8
 - Incomplete abortion, D2, D4*t*
 - Incontinence, urinary, menopause and, V3–V4
 - Inevitable abortion, D2, D4*t*
 - Infant mortality, A2–A5
 - Infants of diabetic mothers (IDM), E34–E41
 - diagnosis of, E35
 - incidence of, E34, L16
 - management of, E39–E41
 - medical problems of, E36–E38
 - outcome of, E34
 - pathophysiology of, E38–E39
 - physical characteristics of, E35
 - significance of, E34–E35
 - Infections. *See also specific types*
 - maternal
 - signs of, L24
 - and spontaneous abortion, D1
 - perinatal and neonatal, J1–J20
 - breastfeeding and, M1–M2
 - clinical manifestations of, J6–J8, J7*t*
 - congenital, J13–J20
 - definition of, J1
 - diagnosis of, J6–J9
 - fetal, J3, J4*t*
 - intrapartum, J4–J6, J5*t*
 - late, J6
 - nosocomial, J6
 - outcome of, J6
 - pathogenesis of, J2
 - postpartum, early, J4–J6
 - risk factors for, J1–J2, L24
 - significance of, J1
 - signs of, L25
 - therapy for, J11
 - Infertility, T1–T13
 - definition of, T1, T2
 - female, evaluation of, T4–T8, T10–T11
 - guidelines on provision of services for, T2–T3
 - incidence of, T1, T2
 - investigation of, T2–T3
 - flow sheet of, T10–T11
 - Influenza
 - rate of, A3*f*
 - as teratogen, C2, C3*t*
 - Inguinal lymphadenopathy, infections associated with, J42–J54
 - Inheritance, multifactorial, of congenital defects, C2
 - Injections, long-acting contraceptive, S8–S10
 - advantages of, S8
 - counseling before, S8
 - disadvantages of, S8
 - dosage for, S9
 - effectiveness of, S9
 - health benefits of, S9–S10
 - patient selection for, S8–S9
 - precautions for, S9
 - side effects of, S9
 - Insulin therapy, for diabetes in pregnancy, E22–E25
 - Intraductal papilloma, P11*t*
 - Intrapartum infections, J4–J6, J5*t*
 - Intrauterine device (IUD), S12–S19
 - complications with, S13–S19
 - contraindications for, S12–S13
 - as emergency postcoital contraception, S6
 - insertion of, S13
 - patient selection for, S12
 - and pelvic inflammatory disease, J67
 - Intrauterine growth restriction (IUGR). *See* Fetal growth restriction
 - Intubation, endotracheal, in neonatal resuscitation, F20, F22–F23, F26*t*
 - Iron deficiency anemia, prenatal care for, B3
 - Iron pills, in postpartum period, I8
 - Ischemic hypoxia, K1
 - Isoimmunization, and prenatal care, B4
 - IUD. *See* Intrauterine device
 - IUGR (intrauterine growth restriction). *See* Fetal growth restriction
- J
- Jarisch-Herxheimer reaction, to syphilis therapy, J44
 - Jaundice, neonatal, L40–L45
 - breast milk, L45
 - etiology of, L40–L41
 - monitoring of, L41–L42
 - significant, L41
 - treatment of, L44
 - work-up for, L42–L43
- K
- Kaplan-Meier method, V13
 - Kegel's exercises, I10
 - Koop, C. Everett, Y1
- L
- Labetalol
 - for chronic hypertension in pregnancy, E6

for preeclampsia, E5–E6
 Labia adhesions, X5
 Labor, G1–G6. *See also* Post-term pregnancy
 active phase of, G3–G5, G3*t*
 protraction/arrest disorders in, G4–G5,
 G4*t*
 definitions of, G1, G2
 latent phase of, G2–G3
 induction during, G2–G3, G2*t*
 premature, F8–F10, N3
 process of, G1*f*
 second stage of, G5–G6
 third stage of, I1–I2
 VBAC, G6
 Lactation. *See* Breastfeeding
 Laparoscopy, in fertility evaluation, T6, T7, T8
 Large-for-gestational-age (LGA) infants
 of diabetic mothers, E35
 incidence of, L16
 physical characteristics of, L16
 problems anticipated in, L16
 significance of, L16
 Last menstrual period (LMP), in gestational age
 assessment, B1
 Latent syphilis, J45–J46
 Leukorrhea, R1–R2
 etiology of, R1, R3*t*–R4*t*
 evaluation of, R2, R3*t*–R4*t*
 treatment of, R2, R3*t*–R4*t*
 Levonorgestral capsules, S7–S8
 LGA. *See* Large-for-gestational-age
 LGV. *See* Lymphogranuloma venereum
 LH. *See* Luteinizing hormone
 Lice, pubic, treatment of, J67–J68
 Lichen sclerosis, X5, X6*f*
 Lips, anomalies of, L17
Listeria monocytogenes, J30–J31
 clinical manifestations of, J31
 diagnosis of, J31
 treatment of, J31
 LMP. *See* Last menstrual period
 Lochia, in postpartum period, I8
 Low-grade squamous intraepithelial lesions
 (LSIL), management of, Q5, Q13*f*, Q14*f*,
 Q15*f*
 Lunelle, S10
 Lung disease
 atelectatic, L47
 obstructive, L47
 restrictive, L47
 Lungs, neonatal assessment of, L10
 Luteal phase defect, and spontaneous abortion,
 D1
 Luteinizing hormone (LH), and female infertility,
 T5

Lymphadenopathy, inguinal, infections
 associated with, J42–J54
 Lymphogranuloma venereum (LGV), J50
 and sex partners, J50
 treatment of, J50

 M
 Macrosomia
 abnormal labor and, G4
 post-term pregnancy and, F12
 Magnesium sulfate
 for preeclampsia, E4–E5
 for premature labor, F10
 Malformations
 definition of, L28
 sequence of, L29
 Malnutrition, maternal, and fetal growth
 restriction, E10–E11
 Mammography, P4
 diagnosis with, P4, P6
 results of, P5–P6
 screening with, P4
 algorithm for, P7*f*
 recommendations for, P5, P5*t*, P12
 Marijuana use, and birth outcomes, C3
 Mastalgia, P9
 Mastitis, M12, P11*t*
 Mastodynia, P9
 Maternal mortality, A1
 Measles. *See* Rubeola
 Measurements, neonatal, L7
 Meconium aspiration syndrome, L50–L52
 and asphyxia, K4
 clinical signs of, L51
 pathophysiology of, L50
 post-term pregnancy and, F12
 management of, F13–F14
 risk factors for, L51
 treatment of, L51–L52
 x-ray findings with, L51
 Medical history, in prenatal care, B3
 Medications. *See also specific agents*
 and breastfeeding, M3, M13
 and congenital defects, C4–C5
 Medroxyprogesterone acetate, S8–S10
 Membrane rupture. *See* Premature rupture of
 membranes
 Meningitis, treatment of, J60
 Menopause
 definition of, V1
 diagnosis of, V6
 endocrinology of, V1–V2
 evaluation in, V6, V7*t*
 management of
 alternative, V19–V20, V20*t*
 hormone replacement for, V7–V21

- symptoms of, V2–V6
- Menstruation
 - abnormalities of, U1–U8
 - amenorrhea, U1–U4
 - during climacteric, V2
 - dysfunctional bleeding, U5–U8
 - endocrinology of, V2
 - in gestational age assessment, B1
- Metabolic complications, in post-asphyxic neonates, K8, K9
- Methemoglobinemia, and cyanosis, L20
- Methicillin, for newborns, J12*t*
- Methotrexate, for ectopic pregnancies, D9–D10
- Methyldopa, for chronic hypertension in pregnancy, E6
- Milk ejection reflex, strong, M11. *See also* Breast milk
- Missed abortion, D2
- Mole, hydatidiform, D10–D11
- Mondor's disease, P11*t*
- Monocytogenes, *Listeria*, J30–J31
- Mood disturbances, menopause and, V4
- Mortality
 - infant, A2–A5
 - causes of, A3–A5, A3*f*
 - neonatal, A2–A3
 - postneonatal, A2, A4
 - rate of, A2–A4, A2*f*
 - maternal, A1
 - causes of, A1
 - rate of, A1
- Mouth, neonatal assessment of, L9
- MPC. *See* Mucopurulent cervicitis
- Mucopurulent cervicitis (MPC), J63–J64
 - and sex partners, J64
 - treatment of, J64
- Mumps, J30
- Muscle tone, neonatal assessment of, L6

- N
- Naegele's rule, B1
- Nahmias, Andre, J21
- Naloxone, in neonatal resuscitation, F19, F21, F27*t*
- National Diabetes Data Group (NDDG) criteria, E19
- NEC. *See* Necrotizing enterocolitis
- Neck, neonatal assessment of, L9
 - anomalies in, L18
- Necrosis, fat, P11*t*
- Necrotizing enterocolitis (NEC), in infants of diabetic mothers, E38
- Neonatal assessment, L1–L27
 - of anomalies, L17–L18
 - approach to, L1
 - of cardiac emergencies, L25–L27
 - of cardiovascular distress, L19–L23
 - complete examination in, L7–L11
 - in delivery room, L3, L5–L7
 - before discharge, L4–L5
 - gestational age and, L11–L16
 - of infections, L24–L25
 - of maternal lifestyle, L2
 - of medical history, L2
 - before nursery admission, L3–L4
 - questions to ask in, L2–L5
 - of respiratory distress, L23–L24
 - in transitional period, L3
- Neonatal Resuscitation Program (NRP), F15, F28*t*
- Neoplasia
 - cervical, Q2
 - intraepithelial, risk factors for, Q2
 - and leukorrhea, R4*t*
- Neural tube defects (NTDs), prenatal screening for, B5–B6, C7
- Neurological exam, newborn, L11
- Neurosyphilis, J46
- Nicotine. *See also* Smoking
 - effects of, L37
- Nifedipine, for preeclampsia, E6
- Nipples
 - breastfeeding complications with, M8–M10
 - cracked, M10
 - discharge from, P8–P9, P9*t*
 - flat/inverted, M8–M9
 - large/elongated, M9
 - neonatal anomalies in, L18
 - sore, M9–M10
 - thrush, M10
- Non-stress testing (NST), for fetal evaluation, H14–H15
- Norplant subdermal implants, S7–S8
- Nose, neonatal assessment of, L9
 - anomalies in, L17
- Nosocomial infections, J6
- NRP. *See* Neonatal Resuscitation Program
- NST. *See* Non-stress testing
- NTDs. *See* Neural tube defects
- Nutrition
 - and fetal growth restriction, E10–E11
 - in postpartum period, I8
- NuvaRing, S10

- O
- Objectives, program, A1–A6
- Observational studies, definition of, V13
- Oligohydramnios
 - and fetal growth restriction, E12
 - post-term pregnancy and, F12
- Omphalocele, L31–L32
- Ophthalmia, gonococcal, J61

neonatorum, J61–J62
 Oral contraception, S2–S6
 advantages of, S3
 common questions and problems on, S5–S6
 complications with, S3–S4
 contraindications for, S2
 effectiveness of, S2
 emergency, S6–S7
 hypertension and, S4
 potency of, S3
 precautions for, S3
 risk with, screening for, S4
 selection of, S3
 use of, S4
 Oral warts, treatment of, J57
 Ortho Evra patch, S10
 Oscillations, in fetal heart rate, H3–H4, H4f
 Osteopenia, definition of, V5
 Osteoporosis
 definition of, V5
 risk factors for, V5
 Ovaries, and female infertility, T4–T6
 Ovary syndrome, polycystic, U3
 Ovulation, abnormal or absent
 amenorrhea and, U1
 and dysfunctional bleeding, U6
 induction of, U2
 Ovum, blighted, D2
 Oxytocin, for protraction/arrest disorders, G5

P
 Palate, anomalies of, L17
 Pap smear tests, Q1–Q6
 abnormal, management of, Q4–Q6
 algorithms for, Q7–Q17
 frequency of, Q3
 technique for, Q3–Q4
 Papilloma, intraductal, P11f
 Papillomavirus, human, J54–J57
 and cervical cancer, Q1–Q2
 Parasympatholytic drugs, and fetal tachycardia, H7
 Paroxysmal atrial tachycardia (PAT),
 assessment of, L26
 Parvovirus, as teratogen, C2
 PAT. *See* Paroxysmal atrial tachycardia
 Patches, estrogen, V18
 Pediculosis pubis, treatment of, J67–J68
 Pelvic inflammatory disease (PID), J64–J67
 diagnosis of, J64–J65
 follow-up for, J67
 IUDs and, J67
 in pregnancy, J67
 and sex partners, J67
 treatment of, J65–J66
 Pelvic organ prolapse, menopause and, V4

 Pelvic pain, W1–W6
 etiology of, W4t–W5t
 evaluation of, W2–W3
 neuropathology of, W1
 symptoms of, W4t
 treatment of, W5–W6
 Penicillin
 desensitization to, J49, J49t
 dosage for newborns, J12t
 skin test, J48
 for syphilis, J44–J49
 congenital, J19, J20
 with penicillin allergy, J48–J49, J49t
 Percutaneous umbilical blood sampling (PUBS),
 for congenital anomalies, C7
 Perianal warts, treatment of, J55–J56
 Perimenopause. *See* Climacteric
 Perinatal asphyxia, E37, K1–K11
 Peripheral cyanosis, L19
 Peritoneal factors, in female infertility, T7–T8
 Pharyngeal gonococcal infections, treatment of,
 J60
 Phototherapy, for infants of diabetic mothers,
 E40
 Physical examinations, in prenatal care, B3
 PID. *See* Pelvic inflammatory disease
 Pituitary gland, in amenorrhea, U3–U4
 Placenta
 abruptio, F2–F4, N3
 physiology of, H1
 postpartum removal of, I1f, I1–I2
 Placenta previa, F1–F2
 management of, F2, F2t
 presentation of, F1–F2
 transport with, N3
 types of, F1
 Pneumonia, neonatal, L54
 clinical findings with, L54
 complications with, L54
 rate of, A3f
 risk factors for, L54
 treatment of, L54
 x-ray findings with, L54
 Poliomyelitis, J30
 Polycystic ovary syndrome, U3
 Polycythemia, neonatal, L58–L60
 clinical signs of, L59
 definition of, L58
 etiology of, L58–L59
 in infants of diabetic mothers, E36
 management of, L59–L60
 Postasphyxia complications, K8–K10
 cardiovascular, K8
 central nervous system, K9, K10
 gastrointestinal, K8, K10
 hematologic, K8, K10

management of, K9–K10
 metabolic, K8, K9
 outcome of, K10–K11
 renal, K8, K9–K10
 Postcoital contraception, emergency, S6–S7
 Postcoital test, in infertility evaluation, T6
 Postmature infants. *See also* Post-term pregnancy
 obstetrical signs of, L13
 physical characteristics of, L13–L14
 prevalence of, L13
 problems anticipated with, L14
 significance of, L13
 Postmaturity syndrome
 clinical presentation of, F12–F13
 definition of, F11
 Postpartum period, I1–I11
 endometritis in, I6
 hemorrhage in, I2–I4
 infections in, J4–J6
 instructions for mothers in, I8–I11
 physiological changes in, I4–I5
 psychological changes in, I5
 puerperal infection in, I5–I6
 recovery period of, I2
 reproductive system changes in, I4–I5
 third stage of labor in, I1–I2
 Post-resuscitation care, F24
 Post-term pregnancy, F11–F14. *See also*
 Postmature infants
 clinical significance of, F11
 complications of, F11–F13
 fetal, F11–F12
 maternal, F11
 neonatal, F12–F13
 definition of, F11
 etiology of, F11
 management of, F13–F14
 outcome of, F14
 Precocious puberty, X5
 Preconception care
 components of, B1
 maternal diabetes and, B1, E26
 risk assessment in, for congenital anomalies,
 B1, C6, C8
 Preeclampsia-eclampsia, E2–E6
 classification of, E2–E3
 definition of, E1
 etiology of, E3
 management of, E3–E6
 antenatal, E3–E4
 intrapartum, E4–E6
 pathophysiology of, E3
 prognosis with, E6
 transport with, N3
 Pregnancy(ies)
 anembryonic, D2
 ectopic, D5–D10
 interval between, as risk factor, B6
 post-term, F11–F14
 Premature infants
 discharge of, L4
 physical characteristics of, L12–L13
 prevalence of, L12
 problems anticipated with, L13
 risk factors for, B6, L12
 significance of, L12
 Premature labor, F8–F10
 definition of, F8
 management of, F8–F10
 preparation for delivery in, F10
 prevention of, F8
 transport with, N3
 Premature rupture of membranes (PROM), F5–
 F6
 diagnosis of, F5
 management of, F5–F6, F6t
 risk factors for, F5
 transport with, N3
 Prenatal care, B1–B8
 components of, B1
 education in, B7–B8
 genetic counseling in, B5–B6
 gestational age assessment in, B1–B2
 goals for, A3, B1
 health inventory in, B3
 laboratory assessments in, B3–B5
 physical examination in, B3
 rate of, A3, A4f, B1
 risk assessment in, B6, B7, B7f
 for congenital anomalies, C6, C6f, C8
 Prepubescent children. *See* Children,
 prepubescent
 Progesterone, in infertility evaluation, T5
 Progestin, menopausal replacement of, V7t
 Progestin-only method, of emergency
 contraception, S7
 PROM. *See* Premature rupture of membranes
 Proteinuria, with gestational hypertension, E7
 Protraction disorders, G4–G5, G4t
 Pruritis, and ectoparasitic infections, J68
 Psychological changes
 menopausal, V4
 postpartum, I5, I10
 Psychological maltreatment, Y1
 Puberty, precocious, X5
 Pubic lice, treatment of, J67–J68
 PUBS. *See* Percutaneous umbilical blood
 sampling
 Puerperal infection, I5–I6
 Puerperal morbidity, I5
 Pulmonary air leak, L52–L53

- clinical findings with, L52
 - pathophysiology of, L52
 - risk factors for, L52
 - treatment of, L53
 - x-ray findings with, L53
 - Pulmonary complications
 - and cyanosis, L20–L22
 - from perinatal infections, J8
 - in post-asphyxic neonates, K9
 - Pulmonary embolism, hormone therapy and, V10–V11
 - Pulmonic stenosis, critical
 - diagnosis of, L26
 - occurrence of, L26
- Q**
- Quickening, in gestational age assessment, B2
 - Quinolone, for gonorrhea, J59
- R**
- Radiation, and congenital defects, C5
 - Raloxifene, V20
 - Randomized controlled trials, definition of, V13–V14
 - Rapid plasma reagin (RPR), for syphilis testing, J44
 - RDS. *See* Respiratory distress syndrome
 - Recurrent abortion, D3
 - Regression, embryonic, D2
 - Relative risk, definition of, V14
 - Renal complications, in post-asphyxic neonates, K8, K9–K10
 - Renal vein thrombosis, in infants of diabetic mothers, E38
 - Reproductive system, postpartum changes to, I4–I5
 - Respiration, neonatal assessment of, L5–L6, L8
 - Respiratory distress, L46–L54
 - diagnosis of, L23
 - etiology of, L47–L54
 - signs of, L23–L24
 - treatment of, L46–L47
 - Respiratory distress syndrome (RDS), L47–L49
 - clinical signs of, L47–L48
 - complications with, L48, L49
 - course of, L48
 - vs. GBS, J23
 - in infants of diabetic mothers, E37
 - pathophysiology of, L47
 - risk factors for, L47
 - treatment of, L48–L49
 - x-ray findings with, L48
 - Rest, postpartum, recommendations for, I8
 - Resuscitation, neonatal, F15–F24. *See also* Postasphyxia complications
 - vs. adult resuscitation, F19–F20
 - care after, F24
 - equipment for, F16, F26*t*
 - medications in, F18–F19, F20, F21, F27*t*
 - personnel for, F16, F17
 - physiologic considerations in, F16
 - principles of, F16–F17
 - procedures of
 - indications for, F20–F21
 - notes on, F21–F24
 - risk factors associated with, F25*t*
 - steps in, F17–F20
 - supplies for, F16, F26*t*
 - teaching materials for, F28*t*
- Rh factor, in prenatal care, B4
- Risk**
- absolute, V13
 - relative, V14
- Risk assessment**
- for congenital anomalies, B1, C6, C6*f*, C8
 - in preconception care, B1, C6, C8
 - in prenatal care, B6, B7, B7*f*
- RPR. *See* Rapid plasma reagin
- Rubella, J26–J27
 - and breastfeeding, M3
 - clinical manifestations of, J26–J27
 - diagnosis of, J21, J27
 - maternal immunity to, B4
 - prevention of, J21, J22*t*
 - as teratogen, C2, C3*t*
 - in TORCH complex, J21
 - treatment of, J21, J22*t*, J27
- Rubeola, J28–J29
 - clinical manifestations of, J28, J29
 - diagnosis of, J28–J29
 - treatment of, J29
- Ruptured membranes. *See* Premature rupture of membranes
- S**
- Sarcoma botryoides, X5
 - Scabies, J68
 - treatment of, J68
 - Sclerosis, lichen, X5, X6*f*
 - Selective estrogen receptor modulators (SERMs), V20
 - Selective intrapartum chemoprophylaxis, for GBS disease, J23–J24, J26
 - Septal hypertrophy, asymmetrical, in infants of diabetic mothers, E36
 - Septic abortion, D3
 - Sequences, of multiple defects, L29
 - SERMs. *See* Selective estrogen receptor modulators
 - Serum calcium level monitoring, of infants of diabetic mothers, E40
 - Sexual assault and abuse

- of children, signs of, J70, X1, X4–X5
 - STDs from, J69–J70
 - evaluation for, J69–J70
 - Sexual intercourse, postpartum, I8–I9
 - Sexual partners
 - with chlamydial infections, J63
 - with genital herpes, J53
 - with genital warts, J57
 - with gonorrhea, J59
 - with HIV infection, J41
 - with lymphogranuloma venereum, J50
 - with mucopurulent cervicitis, J64
 - with pelvic inflammatory disease, J67
 - Sexuality, menopause and, V5
 - Sexually transmitted diseases (STDs). *See also specific diseases*
 - sexual assault and, J69–J70
 - SGA. *See* Small-for-gestational-age
 - Sheehan syndrome, U3
 - Shock, hemorrhagic, L19
 - SIDS. *See* Sudden infant death syndrome
 - Silicone breast implants, P10
 - Single gene defects, C1–C2
 - Skin, neonatal assessment of, L8
 - Skull, neonatal assessment of, L8
 - Small-for-gestational-age (SGA) infants
 - obstetrical signs of, L15
 - physical characteristics of, L15–L16
 - prevalence of, L15
 - problems of, L16
 - risk factors for, L15
 - significance of, L15
 - Smoking, maternal, L36–L39
 - and fetal growth restriction, E10
 - management of, L38–L39
 - mechanisms of, L37–L38
 - rate of, A5, A5f
 - and SIDS, A4
 - significance of, C3, L36–L37, L37t
 - and spontaneous abortion, D1
 - Sodium bicarbonate, in neonatal resuscitation, F18–F19, F21, F27t
 - Spectinomycin, for gonorrhea, J58, J60
 - Spermicidal foam, S11
 - Spine, neonatal assessment of, L10
 - Spontaneous abortion, D1–D5
 - categories of, D2–D3, D4t
 - etiology of, D1–D2
 - incidence of, D1
 - management of, D3–D5
 - Squamous cells of undetermined significance, atypical, management of, Q5, Q9f, Q10f
 - Squamous intraepithelial lesions, management of, Q5–Q6, Q11f, Q13f, Q14f, Q15f, Q16f
 - Stabilization, neonatal, before transport, O2
 - Stagnant hypoxia, K1
 - STDs. *See* Sexually transmitted diseases
 - Stein-Leventhal syndrome, U3
 - Stenosis, critical pulmonic, L26
 - Sterilization, surgical, S11–S12
 - Sternum, anomalies of, L18
 - Streptococcus* infections, group B beta hemolytic, B4, J23–J26
 - Stroke, hormone therapy and, V10–V11
 - Strong milk ejection reflex (MER), M11
 - Substance abuse, and congenital anomalies, C3–C4
 - Sudden infant death syndrome (SIDS)
 - rate of, A3f, A4, A4f
 - risk factors for, A4
 - Supraventricular tachycardia (SVT), L26
 - B₂-sympathomimetic drugs, for premature labor, F10
 - Syndromes. *See also specific syndromes*
 - anomalies associated with, L17–L18
 - definition of, L29
 - Syphilis, J43–J49
 - congenital, J17–J20
 - clinical presentation of, J18
 - diagnosis of, J19, J21, J46–J47
 - epidemiology of, J17–J18
 - follow-up for, J48
 - pathophysiology of, J17
 - prevention of, J21, J22t
 - in TORCH complex, J21
 - treatment of, J19–J20, J21, J22t, J47
 - latent, J45–J46
 - maternal, prenatal screening for, B4
 - neurosyphilis, J46
 - in older infants/children, J48
 - primary, J45
 - secondary, J45
 - tertiary, J46
 - tests for, J43–J44
 - treatment of, J44–J49
 - penicillin allergy and, J48–J49, J49t
 - reaction to, J44
- T
- Tachycardia
 - fetal, H7
 - supraventricular, L26
 - Tachypnea, transient, L49–L50
 - clinical signs of, L49
 - complications with, L50
 - course of, L50
 - pathophysiology of, L49
 - risk factors for, L49
 - treatment of, L50
 - x-ray findings with, L49–L50
 - TAVR. *See* Total anomalous venous return

Teenagers. *See* Adolescents
 TEF. *See* Tracheoesophageal fistula
 Teratogenic infections, C2–C3
 Tertiary syphilis, J46
 Testicular feminization syndrome, U3
 Tetanus vaccination, in pregnancy, C3t
 Thelarche, premature, X7
 Thick blood syndrome. *See* Hyperviscosity syndrome
 Thorax, neonatal assessment of, L9
 Threatened abortion, D2, D4t
 Thrush nipples, M10
 Tobramycin, for newborns, J12t
 Tocolytics, for premature labor, F9
 Tongue, neonatal assessment of, L9
 anomalies in, L17
 TORCH complex, J21–J22
 diagnosis of, J21
 prevention of, J21, J22t
 treatment of, J21, J22t
Torulopsis glabrata, and leukorrhea, R3t
 Total anomalous venous return (TAVR)
 clinical findings with, L26
 occurrence of, L26
 Toxoplasmosis, J27–J28
 clinical manifestations of, J27, J28
 diagnosis of, J21, J27–J28
 prevention of, J21, J22t
 in TORCH complex, J21
 treatment of, J21, J22t, J28
 Tracheoesophageal fistula (TEF), L30–L31
 Transdermal estrogen, V18
 Transient tachypnea, L49–L50
 Transport, emergency
 maternal, N1–N4
 considerations in, N3–N4
 indications for, N1, N2
 protocol for, N1
 neonatal, O1–O3
 indications for, O1
 preparation for, O2–O3
 stabilization before, O2
 Transposition
 clinical/lab findings with, L25
 occurrence of, L25
Trichomonas vaginalis, R3t, R5f, R6f
 Trisomies, screening for, C7
 Trunk, neonatal assessment of, L10
 Tubal factors, in female infertility, T7
 Tuberculosis
 breastfeeding with, M3
 prenatal screening for, B4
 Tumors, pediatric, X5

U
 Ulcers, genital, infections associated with, J42–J54
 Ultrasound examinations
 for congenital anomalies, C6
 for fetal growth restriction, E12–E13
 for gestational age assessment, B2
 for infertility evaluation, T5, T6, T8
 Umbilical blood flow, H2
 Umbilical blood sampling, percutaneous, for congenital anomalies, C7
 Umbilical cord anomalies, L18
 Umbilical vessel catheterization (UVC), in neonatal resuscitation, F21, F24, F26t
 Urethral meatus warts, treatment of, J56–J57
 Urethral prolapse, X5, X6f
 Urinary frequency, menopause and, V3–V4
 Urinary incontinence, menopause and, V3–V4
 Urine culture, in prenatal care, B4–B5
 Urogenital atrophy, menopause and, V3
 Uterine bleeding
 abnormal, hormone therapy and, V19
 dysfunctional, U5–U8
 etiology of, U5–U8
 evaluation of, U6–U7
 pathophysiology of, U6
 treatment of, U7–U8
 Uterine blood flow, H1–H2
 Uterine contractions
 and fetal heart rate, H3, H3f, H15–H16
 normal rates for, H3
 Uterine size estimates, in gestational age assessment, B1
 Uterus
 in amenorrhea, U2
 in female infertility, T6–T7
 postpartum inversion of, I4, I9
 postpartum pains in, I9
 UVC. *See* Umbilical vessel catheterization

 V
 Vaccinations
 for hepatitis, J35t, J36t
 in pregnancy, C3t
 Vaginal area suture care, in postpartum period, I8
 Vaginal birth after cesarean delivery (VBAC), G6
 Vaginal bleeding
 pediatric, X4–X7
 postpartum, I8
 Vaginal cysts, pediatric, X7
 Vaginal microflora, in prepubescent children, X2
 Vaginal warts, treatment of, J56
 Vaginosis, bacterial, and leukorrhea, R3t
 Vancomycin, for newborns, J12t
 Varicella, J29–J30

- clinical manifestations of, J30
- diagnosis of, J30
- as teratogen, C2, C3*t*
- treatment of, J30
- Varicella zoster immune globulin (VZIG), C2
- VBAC. *See* Vaginal birth after cesarean delivery
- Venereal Disease Research Laboratory (VDRL),
 - for syphilis testing, J44
- Venous admixture, L20
- Venous return, total anomalous, L26
- Visceral disease, acute, W2–W3
- Vital signs, neonatal assessment of, L7–L8
- Vitamin(s), in postpartum period, I8
- Vitamin A, and congenital defects, C4
- Volume expanders, in neonatal resuscitation,
 - F19, F21, F27*t*
- Vulvovaginitis, R1–R6
 - atrophic, R4*t*
 - contact, R4*t*
 - pediatric, X4
 - etiology of, X4
 - treatment of, X4
- VZIG. *See* Varicella zoster immune globulin

W

- Warts, genital, J54–J57
- Weight
 - low birth
 - and mortality, A3, A3*f*
 - rate of, A3*f*
 - maternal
 - in pregnancy, B8
 - prepregnancy, B8
 - menopausal changes in, V4
- Women's Health Initiative (WHI) study of
 - hormone therapy, V8–V16
- World Health Organization (WHO), diagnostic
 - criteria for diabetes, E19, E33

X

- X-linked defects, C1

Y

- Yuzpe method, of emergency contraception,
 - S6–S7